Form 8-K - Current report:
SEC Accession No. 0001193125-24-212168
Filing Date
2024-09-03
Accepted
2024-09-03 17:05:01
Documents
17
Period of Report
2024-09-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d852765d8k.htm   iXBRL 8-K 33228
2 EX-4.1 d852765dex41.htm EX-4.1 67355
3 EX-5.1 d852765dex51.htm EX-5.1 15517
4 EX-99.1 d852765dex991.htm EX-99.1 169238
8 GRAPHIC g852765dsp18.jpg GRAPHIC 3937
  Complete submission text file 0001193125-24-212168.txt   494620

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA atra-20240903.xsd EX-101.SCH 2853
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20240903_lab.xml EX-101.LAB 18757
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20240903_pre.xml EX-101.PRE 11712
19 EXTRACTED XBRL INSTANCE DOCUMENT d852765d8k_htm.xml XML 3783
Mailing Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320
Business Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320 805-623-4244
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 241274902
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)